Alethium Health Systems

Site user training ensures all involved are well-prepared to maintain high standards in protocol compliance, patient safety, and data integrity. Effective training prevents errors and fosters accountability, essential for successful trials. #ClinicalTrials #MedicalAdvancements #FDAGuidance #SiteUserTraining #PatientSafety #DataIntegrity #Compliance

Rare disease research faces significant hurdles including limited budgets and small participant pools, compounded by the high costs of adopting eClinical trial platforms. Alethium Health is breaking cost barriers for rare disease by designing customizable solutions at competitive pricing. 🚀 #RareDiseaseResearch #eClincalTrials

From improved data capture rates and data quality to increased participant satisfaction, ePROs offer numerous advantages that reflect the ongoing digital transformation in clinical research. Stay ahead with Alethium's eClinical Platform. 🧑🏽💻 #ePROs #ClinicalTrials #DigitalPlatform

In the digital era, preserving the Belmont Report's policies for participant safety and research integrity demands purpose-built technology. Alethium ensures the highest level of efficacy in patient-centered trials and protects participant safety across all consent scenarios. 🧑🏾💻 #eClinicalTrials #EthicalClinicalTrials

Day 2 Highlight at World Orphan Drug Congress in Boston 🌐 Industry insights on partnering in the rare disease space struck a chord with us. Panelists discussed the advantages of partnerships between large and small biopharma and pharma companies. While established organizations can bring more resources to the development of medical treatments, smaller companies often have a deeper understanding of rare diseases and innovative approaches to problem-solving. 💡 Our agile team at Alethium Health has designed our clinical trial platform to anticipate nuanced needs and challenges before they happen. We’ve optimized trials by adjusting for patient or caregiver struggles, such as incorporating televisits and providing additional translations, to make clinical trials globally accessible at exceptional speed, reduced costs, and minimal risk. 🚀 #ClinicalTrials #OrphanDrugCongressUSA #DigitalClinicalTrials #RareDisease

Currently attending the World Orphan Drug Congress in Boston, the Alethium team (Joseph Farrell, Brant DeBow and Carissa Sinclair) found Rachael Sawaya's perspective on mobile visits in rare disease research to be particularly noteworthy. 💡 Patient enrollment and retention remain major obstacles in rare disease medical research, and Sawaya illustrated how mobile visits in clinical trials can bridge that gap. ✅ Mobile visits ease the burden on patients and their families to travel, leading to enhanced participation and compliance. ✅ Researchers can engage with participants who may live in remote or underserved areas, broadening their pool of potential participants. ✅ Reaching more participants, researchers can achieve a more diverse study population, which is essential for understanding rare diseases. ✅ In-home visits enable real-time monitoring of participants' health and treatment progress, offering researchers more accurate and timely data for the study. ✅ Remote training for local healthcare providers expands expertise in areas with limited sites. At Alethium Health, our platform integrates mobile visits to streamline trial protocols and enable convenient participant-researcher interactions. By simplifying data collection and monitoring, we help drive progress in rare disease research without logistical complications. 🌐 #ClinicalTrials #WorldOrphanUSA #ClinicalTrialsMobileVisits

Understanding the nuances of submitting participant materials in the US and the EU is crucial for researchers, sponsors, and regulatory professionals. It ensures compliance with ethical standards, protects participants' rights, and facilitates the smooth execution of clinical trials across international borders. This article outlines the key differences between US and EU regulations. 🌐 #ClinicalTrials #RegulatoryCompliance #IRBs

The Alethium Health team is excited to attend the World Orphan Drug Congress USA 2024 on April 23- 25 in Boston, MA. From leading orphan pharmaceutical and biotech companies to regulatory authorities and solution providers, this conference attracts the entire rare disease ecosystem to improve access to life-saving therapies for rare disease patients. 🌐 Here at Alethium, we are thrilled about our role in transforming rare disease research through our patient-centric digital platform. Our newest eCOA, consent, and telehealth solution supports complex global trials for any size or budget. 📈 Discover firsthand how the Alethium eClinical Platform is the value-based solution for complex global trials. Meet with Brant DeBow, Joseph Farrell, Carissa Sinclair in the Networking Zone between Theater 3 and Theater 4. We’d love to hear about your next clinical trial. 💡 https://lnkd.in/giQtpZJX #ClinicalTrials #WorldOrphanUSA

Alethium's CEO, Joseph Farrell, recently attended the Advanced Therapies Congress in London, gathering industry leaders, startups, and innovators dedicated to advancing gene therapy treatments. ⚕️ Among the highlights was Professor Uta Griesenbach's contribution to gene therapy advancements for rare respiratory diseases. Although gene therapy holds great potential for treating inherited conditions unresponsive to conventional medicine, the challenge is creating a gene transfer agent to deliver a functional gene to target cells effectively. 🧬 The three universities that make up the UK Respiratory Gene Therapy Consortium (GTC), have developed a promising gene transfer agent for cystic fibrosis. Licensed to Boehringer Ingelheim, this technology has spurred the creation of AlveoGene, a startup primed to tackle rare lung diseases, beginning with alpha-1 antitrypsin deficiency. 🚀 Transformative research in gene therapy requires a pivotal ally. The Alethium eClinical Platform translates complex protocols into patient-centric clinical trials with unmatched security, compliance, and efficiency—regardless of complexity, budget, or scale. 🌐 Let's drive innovation together. 🤝 #ClinicalTrials #GeneTherapy #eClinicalTrialPlatforms #adtherapies2024

Rare diseases affect a small percentage of the population, but collectively, their impact is felt by over 300 million people worldwide, as well as their families and society at large. 🌐 The United Nations’ Resolution on Persons Living with a Rare Disease calls for concerted efforts to improve their health, social inclusion, and access to treatments and care. In this article, we share the key aspects of the resolution and its implications for Clinical Trials and Life Sciences. 🧪⚕️💊